Clin Osteol 2010; 15(4): 165-168

Recommended procedure for diagnosing and treatment of postmenopausal osteoporosis II. AddendumInformations

J. Rosa

Published: December 11, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosa J. Recommended procedure for diagnosing and treatment of postmenopausal osteoporosis II. Addendum. Osteologický bulletin. 2010;15(4):165-168.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McClung M. Parathyroid hormone for the treatment of osteoporosis. Obstet Gynecol Surv 2004;59:826-832. Go to original source...
    2. Greenspan SL, Bone HG, Ettinger MP et al. Effect of recombinant human parat­ hyroid hormone (1-84) on vertebral fracture and bone mineral density in postme­ nopausal women with osteoporosis. A randomized trial. Ann Intern Med 2007; 46:326-339. Go to original source...
    3. Black DM, Greenspan SL, Ensrud KE et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-1215. Go to original source...
    4. Black DM, Bilezikian JP, Ensrud KE et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-565. Go to original source...
    5. Greenspan SL, Hanley DA, Morris S et al. Bone turnover markers and BMD re­ main elevated in postmenopausal osteoporotic women through a full 24 months of treatment with human parathyroid hormone 1-84 (PTH) [abstract no. F389]. J Bone Miner Res 2006;21 (Suppl 1): abstract No. F389
    6. Recker RR, Bare SP, Smith SY et al. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone 2009;44:113-119. Go to original source...
    7. Moen MD, Scott LJ. Recombinant full-length parathyroid hormone (1-84). Drugs 2006;66:2371-2381. Go to original source...
    8. Souhrn údajů o přípravku, Preotact, 100 mikrogramů prášku pro přípravu injekč­ ního roztoku s rozpouštědlem, 31. 5. 2007, přístup 30. 7. 2010.. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000659/ human_med_000984.jspμrl=menus/medicines/medicines.jsp&jsenabled=true http://www.ema
    9. Antoniucci DM, Deborah E. Sellmeyer DE, Bilezikian JP et al. Elevations in se­ rum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis J Clin Endocrinol Metab2007;92:942-947. Go to original source...
    10. Díaz-Curiel M, Hosking D, Brandi M, Hyldstrup LH, Felsenberg D. Serum cal­ cium levels in postmenopausal women with osteoporosis after 1, 6 and 12 months of PTH (1-84) treatment - the latest results from the PEAK trial. Bone 2009;44 Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.